These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15384008)

  • 1. The edematogenic properties of insulin.
    Kalambokis GN; Tsatsoulis AA; Tsianos EV
    Am J Kidney Dis; 2004 Oct; 44(4):575-90. PubMed ID: 15384008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones, insulin resistance and obesity: Finding a balance.
    Wilding J
    Int J Clin Pract; 2006 Oct; 60(10):1272-80. PubMed ID: 16981971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.
    Ruaño G; Bernene J; Windemuth A; Bower B; Wencker D; Seip RL; Kocherla M; Holford TR; Petit WA; Hanks S
    Clin Chim Acta; 2009 Feb; 400(1-2):48-55. PubMed ID: 18996102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adverse effects of insulin sensitisers and biguanides].
    Kanazawa A; Kawamori R
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():189-92. PubMed ID: 18074537
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of insulin and weight gain: optimizing diabetes nutrition therapy.
    Daly A
    J Am Diet Assoc; 2007 Aug; 107(8):1386-93. PubMed ID: 17659906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
    Russell-Jones D; Khan R
    Diabetes Obes Metab; 2007 Nov; 9(6):799-812. PubMed ID: 17924864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K; Davies M
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin oedema?
    Zenda T; Murase Y; Yoshida I; Muramoto H; Okada T; Yagi K
    Eur J Gastroenterol Hepatol; 2003 May; 15(5):545-9. PubMed ID: 12702914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin treatment and the problem of weight gain in type 2 diabetes.
    Carver C
    Diabetes Educ; 2006; 32(6):910-7. PubMed ID: 17102158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin edema in a child with diabetes mellitus type 1.
    Rostami P; Sotoudeh A; Nakhaeimoghadam M; Rabbani A; Rezaei N
    Turk J Pediatr; 2012; 54(3):309-11. PubMed ID: 23094546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled human [rDNA origin] insulin, a novel formulation for diabetes mellitus.
    Pham DQ; Cohen H; Chu V
    J Clin Pharmacol; 2007 Jul; 47(7):890-903. PubMed ID: 17585117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.
    Cekmen N; Cesur M; Cetinbas R; Bedel P; Erdemli O
    J Intensive Care Med; 2006; 21(1):47-50. PubMed ID: 16698744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC
    Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinedione-associated congestive heart failure and pulmonary edema.
    Mikhail NE; Wali S; Cope D
    Mayo Clin Proc; 2004 Apr; 79(4):571-2; author reply 575-7. PubMed ID: 15065626
    [No Abstract]   [Full Text] [Related]  

  • 20. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA; Perez A; Zhang J;
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.